7 results about "Hypertrophic scars" patented technology

The application discloses a kind of active targeting hyperplastic scar's biomimetic hybrid delivery vehicle and its preparation method and application.The application uses scar fibroblast membrane protein, cationic delivery vehicle and siRNA and other materials, realizes the hybridization of cell membrane and cationic delivery vehicle by ultrasonic co-extrusion technology, and gives the immune escape and homologous targeting ability of carrier;Efficient loading of TGF-β1 siRNA is realized by using electrostatic self-assembly, so as to construct a biomimetic transdermal delivery system with active targeting characteristics.The biomimetic hybrid delivery vehicle not only provides an innovative approach for the root cause treatment of hyperplastic scar, but also opens up a new way for gene intervention of other skin fibrosis and inflammation-related diseases, and has important clinical translation value.

The application belongs to the field of new use of drugs, and more particularly relates to application of 3-Deazaadenosine in preparation of a therapeutic drug for treating hypertrophic scars. 3-Deazaadenosine is an S-adenosylhomocysteine hydrolase inhibitor, and has antiviral, anti-inflammatory and other activities. Experiments show that the compound can significantly reduce the modification level of m6A in fibroblasts in hypertrophic scar tissue, inhibit the proliferation and migration of fibroblasts, promote the apoptosis of fibroblasts, and also can reduce the expression levels of Collagen I, Collagen III and alpha-SMA in fibroblasts. Therefore, the compound can be used for preparing a drug for relieving or treating hypertrophic scars, and has important clinical application value.

This invention discloses a combination of biomarkers, a kit, and their applications for detecting hypertrophic scars (HTS). The biomarker combination includes a core biomarker and / or auxiliary biomarker 1 and / or auxiliary biomarker 2; the core biomarker is ABCC9 and CSPG4, auxiliary biomarker 1 is RGS5 and ACTA2, and auxiliary biomarker 2 is PDGFRB and TRPC6. This invention also provides a kit containing the above biomarker combination detection reagents and a drug screening method. This invention reveals for the first time that pathological pericytes are the core fibrotic cells in HTS, breaking through the traditional understanding that fibroblasts are the dominant cells. By targeting and inhibiting the abnormal activation, proliferation, and transdifferentiation of pericytes into myofibroblasts, the generation of myofibroblasts and matrix deposition are curbed at the source, providing a new strategy for precision treatment of HTS. Compared with traditional therapies, this approach has higher specificity and can achieve early molecular warning and quantitative detection of trace tissues for HTS, effectively overcoming the lag and subjectivity of clinical morphological diagnosis.

The application discloses a kind of active delivery system of load ABPC-EVs and its application in the preparation of preventing or treating hyperplastic scar, belong to the field of biological medicine technology.The active delivery system of load ABPC-EVs described above is composed of ABPC-EVs and drug delivery system.The application utilizes ABPC-EVs as core biological active substance, by constructing active delivery system, is applied to the treatment and prevention of hyperplastic scar, can accurately intervene the abnormal metabolism of fibroblast, inhibits the pathological accumulation of collagen fiber, breaks through the dense tissue barrier caused by hyperplastic scar, realizes the accurate delivery of drug, and then realizes the physical flat of hyperplastic scar, color improvement and physiological reconstruction, solve the problems, such as lack of accurate physical-biological synergistic intervention, poor tissue remodeling quality and low bioavailability, in the prior art for treating hyperplastic scar, has great clinical application prospect.

This invention discloses a hypoallergenic traumatic scar repair spray, belonging to the field of skin trauma repair technology. The spray, per 100mL volume, is formulated as follows: 35.0g medical-grade polydimethylsiloxane, 1.2g asiaticoside, 0.8g onion bulb extract, 0.5g allantoin, 0.6g D-panthenol, 0.3g compound sodium hyaluronate, 0.4g tocopheryl acetate, 0.2g tranexamic acid, 0.3g β-glucan, 4.0mL medical-grade glycerin, 3.0mL food-grade propanol, 0.15g carbomer 940, appropriate amount of arginine, and purified water to 100mL. This invention utilizes a multi-pathway synergistic effect, combining medical-grade silicone for hydration, centella asiatica extract for collagen remodeling, onion extract for inhibiting hyperplasia, and tranexamic acid for fading pigmentation. It effectively softens, smooths, lightens, and repairs various traumatic scars, including those from surgery, external injuries, and burns. It shows significant improvement in hypertrophic, pigmented, and old scars. This formula is free of hormones, alcohol, fragrances, preservatives, and heavy metals, avoiding common skin allergens such as peanuts, milk, seafood, and pollen. It is gentle and non-irritating, suitable for long-term use on all skin types. The spray formulation is convenient, has good penetration, and high stability, demonstrating promising prospects for industrialization and clinical application.

This invention provides a FAP-targeted engineered exosome for treating hypertrophic scars, its preparation method, and its application, belonging to the field of biopharmaceutical manufacturing technology. After co-incubation with an ferroptosis inducer, the FAP-targeting small molecule ligand SUC-Lys(Ac)-PEG3-UAMC1110 is covalently linked to the exosome membrane surface using an EDC / NH-mediated amide bond coupling strategy to obtain engineered exosomes. These engineered exosomes are then used to prepare microneedle patches. The microneedle patches allow the engineered exosomes to accumulate at the scar site and preferentially enter FAP-highly expressed scar fibroblasts, inhibiting their abnormal proliferation, migration, and pro-fibrotic phenotype, reducing collagen deposition, and promoting hypertrophic scar tissue remodeling. This invention combines the advantages of strong targeting, low off-target toxicity, minimally invasive drug delivery, sustained local retention, and stable efficacy, making it suitable for preparing drugs to treat or improve hypertrophic scars, and possessing good clinical translational potential.

This invention relates to the field of biomedical dressings, specifically disclosing an exosome-loaded tanshinone hypertrophic scar dressing and its preparation method. The dressing comprises an exosome-tanshinone complex, methacrylamide gelatin, oxidized dextran, and a photoinitiator. The key to its preparation lies in: first, using DSPE-PEG-Maleimide as a bridge, covalently coupling the RGD targeting peptide to the exosome membrane via a Michael addition reaction to construct an active targeting carrier; then, efficiently loading tanshinone IIA using electroporation to form a complex; finally, mixing the complex with a gel precursor and cross-linking it under ultraviolet light. This invention solves the problem of easy detachment of the targeting ligand through chemical coupling, and utilizes a dual-network hydrogel to achieve responsive drug release to the MMP-2 enzyme in the scar microenvironment, thereby improving the local anti-fibrotic efficacy while reducing the single-drug dosage and toxic side effects.